Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

160.63 +0.80 (+0.50%)
Streaming Delayed Price Updated: 12:41 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
48 49 Next >
Novavax Price Target Cut By Around 80%, Plus This Analyst Predicts $129 For NIKE
Morgan Stanley cut the price target for NIKE, Inc. (NYSE: NKE) from $149 to $129. NIKE shares fell 0.6% to $99.20 on Thursday. 
Via Benzinga
Longer-Term Use, Early Initiation of Biogen's Experimental Drug For Inherited Rare Disease Slows Disease Progression
Via Benzinga
Looking At Biogen's Recent Whale Trades
Someone with a lot of money to spend has taken a bearish stance on Biogen (NASDAQ:BIIB). And retail traders should know. We noticed this today when the big position showed up on publicly available... 
Via Benzinga
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Biogen Inc.’s Directors and Officers for Breach of Fiduciary Duties – BIIB
From Scott+Scott Attorneys at Law LLP
Via Business Wire
What Are Whales Doing With Biogen
A whale with a lot of money to spend has taken a noticeably bearish stance on Biogen. Looking at options history for Biogen (NASDAQ:BIIB) we detected 28 strange trades. 
Via Benzinga
Has The Controversy Around Falsified Alzheimer's Research Impacted The Path To Finding The Cure?
Finding the cure to Alzheimer’s has confounded researchers for decades. 
Via TheNewswire.com
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
Biogen Whale Trades For September 14
Someone with a lot of money to spend has taken a bearish stance on Biogen (NASDAQ:BIIB). And retail traders should know. We noticed this today when the big position showed up on publicly available... 
Via Benzinga
Hurry! It’s Time to Take Your Profits From These 7 Stocks
Investors are increasingly focused on stocks to sell as they brace for a tough September as the economy's challenges mount. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Biotech Stocks Stand to Benefit as Biden Announces Support for Industry
President Biden has announced a new initiative to help U.S. biotech producers grow. Here's what this news means for biotech stocks. 
Via InvestorPlace
Expert Ratings for Biogen
Over the past 3 months, 6 analysts have published their opinion on Biogen (NASDAQ:BIIB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's... 
Via Benzinga
Has The Controversy Around Falsified Alzheimer's Research Impacted The Path To Finding The Cure?
Finding the cure to Alzheimer’s has confounded researchers for decades. As a disease, Alzheimer’s is highly complex and has a wide range of symptoms, including sleeplessness, wandering, agitation,... 
Via Benzinga
Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock
Cassava is reaching the end of its study on Simufilam, an Alzheimer's treatment, and a third insider just bought shares of SAVA stock. 
Via InvestorPlace
7 F-Rated Stocks to Avoid Now
The following equities may be household names, but current market conditions mean they’re definitely stocks to avoid now. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
  This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Covid Exposed A 'Brain Health Pandemic' — Here's How Biotech Stocks Like Biogen, Sage Therapeutics Could Help
Today's depression drugs don't fit many patients' needs. Biotech companies may change that. 
Via Investor's Business Daily
Is This Company In A Special Position Even As The COVID-19 Pandemic Affects Cell-Based Therapy Industry?
According to Grand View Research, the global cell therapy market was valued at $7.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 14.5% between 2021 and 2028. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
7 Cheap Blue-Chip Stocks to Buy Before They Rebound
The bear market has hit even top firms. That means investors should consider these cheap blue-chip stocks to buy now. 
Via InvestorPlace
How Is The Market Feeling About Biogen?
Biogen's (NASDAQ:BIIB) short percent of float has fallen 17.34% since its last report. The company recently reported that it has 2.09 million shares sold short, which is 1.43% of... 
Via Benzinga
Bill Gates, Jeff Bezos Unite To 'Change The Course' Of Neurological Disorder Impacting 6.5 Million Americans
It’s a well-known fact that Microsoft Corporation (NASDAQ: MSFT) co-founder Bill Gates, through his Bill & Melinda Gates Foundation, is working toward eliminating infectious diseases and eradicating... 
Via Benzinga
Here's How Much $100 Invested In Biogen 15 Years Ago Would Be Worth Today
Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 2.68% on an annualized basis producing an average annual return of 9.81%. Currently, Biogen has a market capitalization of... 
Via Benzinga
A Monoclonal Antibody Treatment For ALS Could Begin Human Trials By 2023, According To Pasithea
Pasithea Therapeutics Corp. (NASDAQ: KTTA), a biotech company looking for new treatments for psychiatric and neurological disorders, received an AU$1 million (US$694,000) gran 
Via Benzinga
7 Undervalued S&P 500 Stocks to Buy Before Wall Street Catches On
July's heat on Wall Street could start to sizzle in August with these undervalued S&P 500 stocks that are ready to buy. 
Via InvestorPlace
Recap Of Tuesday's Biotech Catalysts - End of The Day Summary
Via Benzinga
FDA Accepts Biogen's Submission For Neurodegenerative Disease Drug Under Priority Review
The U.S. Food and Drug Administration (FDA) has accepted Biogen’s (NASDAQ: BIIB) New Drug Application (NDA) for its lead asset Tofersen for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis... 
Via Benzinga
Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS
From Biogen Inc.
Via GlobeNewswire
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
48 49 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.